Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit

Molecular Partners (NASDAQ:MOLN), a clinical-stage biotech focused on DARPin therapeutics, will participate in TD Cowen’s 7th Annual Oncology Innovation Summit on May 27, 2026, at 11:30am ET.

Rhea-AI Summary

Molecular Partners (NASDAQ:MOLN), a clinical-stage biotech focused on DARPin therapeutics, will participate in TD Cowen’s 7th Annual Oncology Innovation Summit on May 27, 2026, at 11:30am ET.

The fireside chat will be webcast and accessible via the company’s website under the investors tab.

Argus May 27 session

-0.25% close to close Open Argus

Details

News Market Reaction – MOLN

In the May 27 session, MOLN declined 0.25%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Molecular Partners’ participation in TD Cowen’s 7th Annual Oncology Inn...

Analysis

This announcement highlights Molecular Partners’ participation in TD Cowen’s 7th Annual Oncology Innovation Summit with a fireside chat on May 27, 2026 at 11:30am ET. It adds to a recent series of conference and data disclosures around the DARPin oncology pipeline, including MP0712 and MP0317. Investors following the story may focus on how management frames clinical progress, cash runway, and upcoming milestones, given prior updates on Phase 1/2a trials and ongoing Phase 2 development.

Key Figures

Conference edition: 7th Annual Event date: May 27, 2026 Start time: 11:30am ET

Conference edition

7th Annual

TD Cowen Oncology Innovation Summit

Event date

May 27, 2026

Fireside chat schedule

Start time

11:30am ET

Fireside chat at TD Cowen summit

Historical Context

5 past events · Latest: May 12

5 events

1. May 12

   Q1 results, pipeline

   24h Move

   -1.0%

   Reported Q1 2026 financials and initiation of MP0712 and MP0317 studies.

2. May 04

   Conference presentations

   24h Move

   +3.9%

   Announced multiple oral presentations for DLL3-targeting Radio-DARPin MP0712.

3. May 01

   Phase 1 data

   24h Move

   +0.2%

   Published Phase 1 MP0317 data in Nature Cancer with favorable safety profile.

4. Apr 19

   AACR 2026 posters

   24h Move

   +4.9%

   Presented preclinical and early clinical data for MP0632 and MP0712 at AACR.

5. Apr 14

   AGM, governance

   24h Move

   +1.4%

   AGM approved all proposals and elected a new board member despite reported losses.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

darPin therapeutics

1 terms

darPin therapeutics medical

"developing a new class of custom-built protein drugs known as DARPin therapeutics"

Darpin therapeutics are medicines built from designed ankyrin repeat proteins — small, engineered proteins crafted to stick to specific molecules involved in disease, much like a custom key fitting a lock. They matter to investors because their compact, stable design can make treatments easier and cheaper to manufacture, allow targeting of multiple disease mechanisms, and may offer faster development paths compared with traditional biologic drugs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that members of the management team will participate in the following upcoming investor conference.

TD Cowen’s 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA:

• Fireside chat on Wednesday, May 27, 2026 beginning at 11:30am ET
  
  

The event will be webcast and available on the Molecular Partners website, under the investors tab.

About Molecular Partners AG 
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of protein drugs known as DARPin therapeutics, for medical challenges other treatment modalities cannot readily address. Molecular Partners leverages the key properties of DARPins to design and develop differentiated therapeutics for cancer patients, including targeted radiopharmaceuticals and next-generation immune cell engagers. The Company has proprietary programs in various stages of pre-clinical and clinical development, as well as programs developed through partnerships with leading pharmaceutical companies and academic centers. Molecular Partners, founded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn and Twitter / X @MolecularPrtnrs.

For further details, please contact:
Seth Lewis, EVP Corporate Finance
Concord, Massachusetts, U.S.
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361

Laura Jeanbart, PhD, Head of Portfolio Management & Communications
Zurich-Schlieren, Switzerland
laura.jeanbart@molecularpartners.com
Tel: +41 44 575 19 35

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Molecular Partners (MOLN) present at TD Cowen’s 7th Annual Oncology Innovation Summit?

Molecular Partners will join TD Cowen’s 7th Annual Oncology Innovation Summit on May 27, 2026, at 11:30am ET. The company announced that management will participate in a fireside chat as part of the oncology-focused investor event.

How can investors watch Molecular Partners’ fireside chat at the TD Cowen oncology summit?

Investors can watch Molecular Partners’ fireside chat via a live webcast available on the company’s website under the investors tab. According to the company, the event will be accessible online at the scheduled time.

What is Molecular Partners (MOLN) and what are DARPin therapeutics?

Molecular Partners is a clinical-stage biotech company developing a new class of custom-built protein drugs called DARPin therapeutics. According to the company, these therapies are designed as tailored protein-based medicines for various disease targets.

Why is Molecular Partners participating in TD Cowen’s Oncology Innovation Summit in May 2026?

Molecular Partners is participating to engage with oncology-focused investors through a fireside chat at TD Cowen’s 7th Annual Oncology Innovation Summit. According to the company, management will discuss its DARPin therapeutic platform and current clinical-stage activities.

Will a replay of Molecular Partners’ May 27, 2026 TD Cowen presentation be available?

The company stated that the TD Cowen Oncology Innovation Summit event will be webcast and available on its website under the investors tab. Investors can check the site after the event for continued access, if provided.